BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28341300)

  • 1. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Jandial DA; Brady WE; Howell SB; Lankes HA; Schilder RJ; Beumer JH; Christner SM; Strychor S; Powell MA; Hagemann AR; Moore KN; Walker JL; DiSilvestro PA; Duska LR; Fracasso PM; Dizon DS
    Gynecol Oncol; 2017 May; 145(2):236-242. PubMed ID: 28341300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
    Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.
    Aghajanian C; Dizon DS; Sabbatini P; Raizer JJ; Dupont J; Spriggs DR
    J Clin Oncol; 2005 Sep; 23(25):5943-9. PubMed ID: 16135465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
    Taylor SE; Li R; Petschauer JS; Donovan H; O'Neal S; Keeler AW; Zamboni WC; Edwards RP; Zorn KK
    Gynecol Oncol; 2015 Sep; 138(3):548-53. PubMed ID: 26111788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
    Kimball KJ; Numnum TM; Kirby TO; Zamboni WC; Estes JM; Barnes MN; Matei DE; Koch KM; Alvarez RD
    Gynecol Oncol; 2008 Oct; 111(1):95-101. PubMed ID: 18692224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
    Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
    Ramirez PT; Landen CN; Coleman RL; Milam MR; Levenback C; Johnston TA; Gershenson DM
    Gynecol Oncol; 2008 Jan; 108(1):68-71. PubMed ID: 17905421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
    Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    Grabosch S; Tseng G; Edwards RP; Lankes HA; Moore K; Odunsi K; Vlad A; Ma T; Strange M; Brozick J; Lugade A; Omilian A; Bshara W; Stuckey AR; Walker JL; Birrer M
    Gynecol Oncol; 2017 Jul; 146(1):137-145. PubMed ID: 28483269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
    Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
    Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N; Sill MW; Mannel RS; Thaker PH; DiSilvestro PA; Waggoner SE; Yamada SD; Armstrong DK; Fracasso PM; Walker JL
    Gynecol Oncol; 2012 Dec; 127(3):506-10. PubMed ID: 22943879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
    Krasner CN; Castro C; Penson RT; Roche M; Matulonis UA; Morgan MA; Drescher C; Armstrong DK; Wolfe JK; Lee H; Supko JG; Seiden M; Birrer MJ; Dizon DS
    Gynecol Oncol; 2019 May; 153(2):223-229. PubMed ID: 30765148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
    Morgan MA; Sill MW; Fujiwara K; Greer B; Rubin SC; Degeest K; Yamada SD; Waggoner S; Coleman RL; Walker JL; Mannel RS
    Gynecol Oncol; 2011 May; 121(2):264-8. PubMed ID: 21277623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.
    Broekman KE; Hof MAJ; Touw DJ; Gietema JA; Nijman HW; Lefrandt JD; Reyners AKL; Jalving M
    Invest New Drugs; 2020 Oct; 38(5):1454-1462. PubMed ID: 32146550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS
    J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
    Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
    Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.